Poherdy is the first FDA-approved interchangeable biosimilar to Perjeta for HER2-positive breast cancer, potentially expanding access and reducing costs. Approved for use in combination with ...
The U.S. Food and Drug Administration (FDA) approved Poherdy (pertuzumab-dpzb) as the first interchangeable biosimilar to ...
Equivocal results of HER2 fluorescent in situ hybridization (FISH) assessment in breast cancer: Diagnostic limitations and therapeutical implications. This is an ASCO Meeting Abstract from the 2012 ...
Conclusion: Patients with normal serum HER-2/neu receiving letrozole demonstrated a significantly greater ORR and CB and longer TTP and TTF than patients receiving tamoxifen. Although in patients with ...
Julie Fisher, MD: Hello, and welcome to Cure Expert Connections on HER2-positive breast cancer. I'm Dr Julie Fisher and I'm a medical breast oncologist at the Levine Cancer Institute in Charlotte, ...
Please provide your email address to receive an email when new articles are posted on . Tiersten: Historically HER2-positive breast cancers were considered to have a poor prognosis compared with other ...
Breast Tumor Section showing nonamplified HER-2/neu (<4 signals/nucleus). Cells are stained with DAPI. Probe is detected with flurorescein. There is perhaps nothing more disturbing to a woman than a ...
ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc., (“ITI”), a privately-held clinical-stage biotechnology company pioneering the study of LAMP-mediated nucleic acid-based immunotherapy, ...
Please provide your email address to receive an email when new articles are posted on . Researchers reported a 41% confirmed ORR among patients with HER2-positive disease. No patients with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback